Form 4: Bio-Techne Executive Receives New Equity Grants
Executive Equity Grant
Steven C. Crouse, President of Diagnostics & Spatial Biology at Bio-Techne, reported the acquisition of new performance restricted stock units, restricted stock units, and stock options.
Summary
- Steven C. Crouse, President Diag & Spatial Bi at BIO-TECHNE Corp, reported changes in beneficial ownership of company securities.
- On March 2, 2026, Mr. Crouse acquired 2,387 Performance Restricted Stock Units (PRSUs), which are contingent rights to receive one share of common stock and vest in full or in part on August 15, 2028, subject to performance goals.
- On March 2, 2026, Mr. Crouse also acquired 735 Restricted Stock Units (RSUs), which vest in three equal annual installments of 245 units on March 2, 2027, March 2, 2028, and March 2, 2029.
- Additionally, on March 2, 2026, Mr. Crouse acquired 1,911 Stock Options with an exercise price of $57.82 and an expiration date of March 2, 2036. These options vest in installments of 478 shares on March 2, 2027, March 2, 2028, and March 2, 2030, and 477 shares on March 2, 2029.
- Following these transactions, Mr. Crouse directly beneficially owns 5,894 shares of common stock.
- His total beneficial ownership of derivative securities includes 18,155 Restricted Stock Units (including PRSUs) and 111,053 Stock Options, each with various vesting schedules and exercise prices.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, indicating continued executive commitment and alignment with long-term company performance through equity incentives, which is generally favorable for governance and stability.
Positives
- The acquisition of new equity grants aligns the executive's long-term interests with those of shareholders, incentivizing performance and retention.
Future Outlook
The vesting schedules for the newly acquired equity awards, extending through 2029 and 2030 for RSUs and options respectively, indicate a long-term retention strategy for the executive and an alignment of future performance with shareholder value.
Industry Context
StockSavvy.ai notes that equity grants are a standard component of executive compensation in the biotechnology and diagnostics industry, designed to align management incentives with long-term shareholder value creation and retention.
Comparison to Industry Standards
- Equity grants are a common compensation practice across industries, including life sciences. The specific size and vesting schedules are typical for executive-level compensation packages in companies like Thermo Fisher Scientific, Danaher Corporation, or Agilent Technologies, which also utilize performance-based and time-based equity awards to incentivize leadership.
Stakeholder Impact
- Shareholders: Potential for increased alignment of executive interests with shareholder value creation through performance-based incentives.
- Employees: Standard executive compensation practices may reinforce overall company compensation philosophy and talent retention efforts.
Next Steps
- Vesting of 245 restricted stock units on March 2, 2027, March 2, 2028, and March 2, 2029.
- Vesting of 478 stock options on March 2, 2027, March 2, 2028, and March 2, 2030, and 477 stock options on March 2, 2029.
- Vesting of 2,387 performance restricted stock units on August 15, 2028, subject to performance goals.
- Ongoing vesting of previously granted restricted stock units and stock options according to their respective schedules.
Key Dates
| Date | Description |
|---|---|
| 08/15/2023 | Options to purchase 6,140 shares vested. |
| 08/15/2024 | Options to purchase 6,140 shares vested; Options to purchase 3,162 shares vested. |
| 05/01/2025 | Options to purchase 1,832 shares vested. |
| 08/15/2025 | Options to purchase 6,140 shares vested; Options to purchase 3,163 shares vested; Options to purchase 4,283 shares vested. |
| 03/02/2026 | Date of earliest transaction, including the acquisition of new Performance Restricted Stock Units, Restricted Stock Units, and Stock Options. |
| 03/04/2026 | Filing date of the Statement of Changes in Beneficial Ownership. |
| 05/01/2026 | 794 restricted stock units vest; Options to purchase 1,832 shares vested. |
| 06/02/2026 | 600 restricted stock units vest; Options to purchase 1,359 shares vested. |
| 08/15/2026 | 1,379 restricted stock units vest; 1,868 restricted stock units vest; 2,176 restricted stock units vest; Options to purchase 6,140 shares vested; Options to purchase 4,284 shares vested; Options to purchase 4,788 shares vested. |
| 03/02/2027 | 245 restricted stock units vest; Options to purchase 478 shares vest. |
| 05/01/2027 | 794 restricted stock units vest; Options to purchase 1,831 shares vested. |
| 06/02/2027 | 600 restricted stock units vest; Options to purchase 1,358 shares vested. |
| 08/15/2027 | 1,869 restricted stock units vest; 2,177 restricted stock units vest; Options to purchase 3,162 shares vested; Options to purchase 4,283 shares vested; Options to purchase 4,788 shares vested. |
| 03/02/2028 | 245 restricted stock units vest; Options to purchase 478 shares vest. |
| 04/01/2028 | Expiration date for 3,856 stock options. |
| 05/01/2028 | Options to purchase 1,832 shares vested. |
| 06/02/2028 | 600 restricted stock units vest; Options to purchase 1,359 shares vested. |
| 08/06/2028 | Expiration date for 19,032 stock options. |
| 08/15/2028 | 2,387 performance restricted stock units vest (if certain performance goals are achieved); 2,176 restricted stock units vest; Options to purchase 4,283 shares vested; Options to purchase 4,787 shares vested. |
| 03/02/2029 | 245 restricted stock units vest; Options to purchase 477 shares vest. |
| 06/02/2029 | Options to purchase 1,358 shares vested. |
| 08/15/2029 | Expiration date for 24,560 stock options; Options to purchase 4,788 shares vested. |
| 03/02/2030 | Options to purchase 478 shares vest. |
| 08/15/2030 | Expiration date for 12,649 stock options. |
| 05/01/2031 | Expiration date for 7,327 stock options. |
| 08/15/2034 | Expiration date for 17,133 stock options. |
| 06/02/2035 | Expiration date for 5,434 stock options. |
| 08/15/2035 | Expiration date for 19,151 stock options. |
| 03/02/2036 | Expiration date for 1,911 stock options. |
Recommendation
holdThis Form 4 filing reports routine equity grants to an executive, which is a standard component of compensation and does not typically indicate a significant change in the company's fundamental outlook or immediate share price catalysts. It reinforces management's long-term alignment but does not provide new information warranting a change in investment stance.
Keywords
BIO-TECHNE, TECH, Steven C. Crouse, Form 4, insider transaction, equity grants, restricted stock units, stock options, executive compensation, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.